The introduction of oral GLP-1 medicines, alongside growing awareness of injectable treatments such as Wegovy and Mounjaro, means patients now have more choice than ever before. Demand for the pills has increased by 350% since the launch in July.

That’s undoubtedly positive, but it has also created a new challenge – increasingly, patients are asking whether they should switch, which option is ‘best’, or whether what they’ve seen online is actually true.

As clinicians, we’re no longer simply helping patients access treatment. We’re helping them navigate an increasingly complex landscape where headlines, social media and anecdotal experiences often sit alongside clinical evidence. Our role in providing clear, personalised guidance has never been more important.

For many patients, the prospect of a tablet rather than a weekly injection is appealing. Some are understandably anxious about needles, while others see tablets as a more convenient option that may fit more easily into everyday life. However, greater choice can also create misconceptions.

One of the most common assumptions is that a tablet is somehow a ‘lighter’ or less effective version of an injectable treatment. In reality, oral semaglutide contains the same active ingredient as the Wegovy injection.

The difference lies in how the medicine is delivered and absorbed, meaning it has different dosing requirements rather than different levels of effectiveness.

Patients may wonder whether they can simply swap between treatments, or even combine them to improve results.

These are understandable questions, but they reinforce why treatment decisions should always be clinician-led. Switching isn’t simply replacing one prescription with another; it requires careful assessment of an individual’s treatment history, current dose, tolerability, lifestyle and wider health needs.

One of the most interesting developments we’ve seen over the past year is that patients are increasingly considering how treatment fits into everyday life, rather than focusing solely on the number on the scales.

Recent research conducted found that considerations around day-to-day feasibility are playing an increasingly important role in treatment decisions. More than four in ten people (41%) using GLP-1 medicines said they worry about keeping medication at the correct temperature while travelling, while 37% are concerned about taking injection pens through airport security.

More than half said they would consider pausing treatment during a holiday, often because they want to enjoy food and drink more freely or are concerned about side effects affecting their trip.

These findings highlight something clinicians are increasingly seeing in practice. Patients aren’t simply asking whether a medicine works; they’re asking how it fits around family holidays, shift work, business travel, social occasions and daily routines.

Respondents described their AI usage more as augmentation of existing commercial workflows – content creation, sales planning, administration – than one that overhauled operations. The respondents who described successful adoption emphasised a blended approach, reducing technical barriers via natural language interfaces and embedding human oversight (‘human in the loop’) to mitigate AI risks.

“[It’s about] the combination of human plus AI... not AI alone”
There were examples of radical workflow change, and one respondent described a process of ‘rewiring marketing’, although this was a work in progress and the precise meaning of the term remained unclear to the respondent.

One concern was that AI efficiencies are reshaping workforce structures, often reducing entry-level roles vital for career progression, demanding fresh talent strategies blending AI skills with experiential learning.

It’s easy to see why oral treatments generate excitement because for someone who travels frequently or finds injections intimidating, removing needles and refrigeration requirements may appear to solve several practical challenges.

However, convenience should not come at the expense of choosing the most clinically appropriate treatment.

Unlike weekly injections, oral semaglutide requires a consistent daily routine. It must be taken on an empty stomach with a small amount of water, before waiting at least 30 minutes before eating, drinking anything other than water or taking other medication. For some patients, that’s entirely manageable.

For others – particularly shift workers, those with unpredictable mornings or individuals taking multiple medicines – it may prove considerably more challenging than a weekly injection.

This is why conversations about adherence are becoming just as important as conversations about efficacy. The best treatment is rarely the one that appears most convenient on paper; it’s the one a patient can realistically and safely incorporate into his or her everyday life over the long term.